^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy

Published date:
07/11/2022
Excerpt:
We enrolled a multicenter cohort of 85 HCC patients treated with atezolizumab and bevacizumab (Atezo/Bev) between 2020 and 2021….Twenty-six patients with a TERT mutation had significantly shorter OS than those without.
DOI:
10.3390/cancers14143367